4
Changes in Ownership
Protalix BioTherapeutics, Inc. Filed Acc 0001144204-15-028486
Options or other derivatives
- Executive VP, R&D acquired 275,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Shaaltiel Yoseph Executive VP, R&D | 2015-03-23 | Grant or award · Stock Options (Right to Buy) | +275,000 | 275,000 | D | ||
Loading xslF345X03/v409798_form4.xml…